Successful wearable device selection for the evolving clinical trials landscape
The number of wearable, connected medical devices (wearable devices) available for use in healthcare and clinical research has increased significantly over the past few years, making it challenging for clinical trial sponsors to know which devices would be most appropriate for their clinical trials. For example, when looking at activity monitors, there are a plethora of different devices available, ranging from commercially available actigraphy to specialized and medically approved devices. This article is designed to help sponsors consider which devices best meet their requirements when running a clinical trial.
First, let’s look at the opportunities that wearable devices offer for patients, sites and sponsors within clinical trials. These include: giving patients ongoing insights about their health; giving sites continuous information about patients that could potentially reduce the number of site visits; and helping sponsors design trial endpoints based on near real-time, continuous, home-based, real-world data, instead of the more traditional, infrequent, site-based data.
Now let’s look at some considerations that can help sponsors select the most appropriate device(s) for their clinical trials:
- What are the trial’s objectives? What are the endpoints and associated measurements and/or assessments?
- How have the devices been validated by the manufacturer, in terms of:
- Data consistency, acceptability and scientific accuracy?
- Intra- and inter-device validity?
- Regulatory considerations?
- Usability?
- Data transmission and interaction?
- Logistics?
Once the opportunities have been evaluated, and the criteria for the best device selection have been reviewed, it is important to work with the right technology and CRO partner. Sponsors should ensure that device providers and CRO partners provide adequate data security and regulatory guidance. All the relevant regulations must be respected to ensure participants’ data are treated confidentially. The regulatory environment is constantly evolving, leaving room for further innovation. It can be daunting to be the first sponsor to use a certain device in a clinical trial but employing the above considerations and getting the green light from the relevant regulatory body early on in the process can make the use of wearable devices an exciting opportunity.
Wearable devices are here to stay and will keep developing to present more possibilities in clinical trials. But there is no need to wait before embracing them – the future of clinical trials is now.
Related Insights
Article
Delivering AI-managed clinical research data: Parexel’s end-to-end automation strategy
Mar 11, 2025
Blog
Membership in Clinical Research Data Sharing Alliance enables Parexel to shape the future of clinical trial data
Sep 7, 2022
Blog
PBPK modeling solutions as a potential risk mitigation strategy for pH dependent DDIs
Mar 15, 2021
Blog
Putting AI to work in your safety program
May 21, 2021
Blog
RBQM is our future: Using holistic risk-based oversight, we can focus on a trial’s most critical factors
Jun 18, 2021
Article
Tencent-Backed Wedoctor Is Going Public: What Are the Next Steps for Chinese Digital Health Companies?
Jun 30, 2021
Article
Evidence Generation Strategy under Germany’s Digital Healthcare: Is More Better?
Aug 6, 2021
Blog
Highlights from ISMPP Asia Pacific Meeting 2021
Sep 20, 2021
Blog
Capitalizing on sensors in clinical trials
Sep 20, 2021
Blog
Actigraphy advances a patient-first approach: Reduce patient burden — and make the most of valuable data
Oct 15, 2021
Blog
Clinical pharmacology, modeling and simulation to support FIH study design
Oct 21, 2021
Blog
CNS Summit Recap: The Future is Collaborative
Nov 22, 2021
Related Insights
Article
Delivering AI-managed clinical research data: Parexel’s end-to-end automation strategy
Mar 11, 2025
Blog
Membership in Clinical Research Data Sharing Alliance enables Parexel to shape the future of clinical trial data
Sep 7, 2022
Blog
PBPK modeling solutions as a potential risk mitigation strategy for pH dependent DDIs
Mar 15, 2021
Blog
Putting AI to work in your safety program
May 21, 2021
Blog
RBQM is our future: Using holistic risk-based oversight, we can focus on a trial’s most critical factors
Jun 18, 2021
Article
Tencent-Backed Wedoctor Is Going Public: What Are the Next Steps for Chinese Digital Health Companies?
Jun 30, 2021
Article
Evidence Generation Strategy under Germany’s Digital Healthcare: Is More Better?
Aug 6, 2021
Blog
Highlights from ISMPP Asia Pacific Meeting 2021
Sep 20, 2021
Blog
Capitalizing on sensors in clinical trials
Sep 20, 2021
Blog
Actigraphy advances a patient-first approach: Reduce patient burden — and make the most of valuable data
Oct 15, 2021
Blog
Clinical pharmacology, modeling and simulation to support FIH study design
Oct 21, 2021
Blog
CNS Summit Recap: The Future is Collaborative
Nov 22, 2021